Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome.


Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 16 01 2023
accepted: 14 07 2023
medline: 17 8 2023
pubmed: 15 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

Thyroid cancer surveillance (TCS) with ultrasound (US) is advised for PTEN hamartoma tumour syndrome (PHTS) patients due to increased thyroid cancer (TC) risk. However, data supporting TCS guidelines are scarce. We aimed to assess the detection and yield of annual TCS with US in adult PHTS patients without a TC history and to evaluate the impact of a reduced US interval on the TCS yield. A retrospective cohort study was conducted, including adult PHTS patients and medical record data between 2005 and 2021. The yield from annual TCS was compared with hypothetical biennial and triennial TCS after two initial US with annual interval by counting delayed detection of nodular growth, thyroid adenoma, and TC. During 279 follow-up years, 84 patients (median age 40 years) underwent 349 US. Thyroidectomy was performed in 6/84 (7%) patients, revealing a minimally invasive follicular TC in one patient aged 22 and a thyroid adenoma in two patients aged 21 and 53. Multiple thyroid nodules were diagnosed in 73/84 (87%) patients (median age 36 years). Nodular growth was detected in 9/56 (16%) patients, and its detection would have been delayed in 4-7% US rounds with biennial TCS, and in 2-6% US rounds with triennial TCS. US-based thyroiditis and indeterminate non-malignant lymph nodes were found in 8/74 (11%) and 7/72 (10%) patients, respectively. Following our findings combined with the literature, we propose starting TCS before age 18 and reducing the follow-up frequency after the initial two US from annual to biennial if no suspicious findings are detected.

Identifiants

pubmed: 37451289
doi: 10.1530/ERC-23-0009
pii: ERC-23-0009
doi:
pii:

Substances chimiques

PTEN protein, human EC 3.1.3.67
PTEN Phosphohydrolase EC 3.1.3.67

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Meggie M C M Drissen (MMCM)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Janet R Vos (JR)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Romana T Netea-Maier (RT)

Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.

Martin Gotthardt (M)

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Nicoline Hoogerbrugge (N)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH